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Abstract
Mammalian brain expresses multiple nicotinic acetylcholine receptor (nAChR) subtypes that differ
in subunit composition, sites of expression and pharmacological and functional properties. Among
known subtypes of receptors, α4β2* and α6β2*-nAChR have the highest affinity for nicotine (where
* indicates possibility of other subunits). The α4β2*-nAChRs are widely distributed, while α6β2*-
nAChR are restricted to a few regions. Both subtypes modulate release of dopamine from the
dopaminergic neurons of the meso-accumbens pathway thought to be essential for reward and
addiction. α4β2*-nAChR also modulate GABA release in these areas.
Identification of selective compounds would facilitate study of nAChR subtypes. An improved
understanding of the role of nAChR subtypes may help in developing more effective smoking
cessation aids with fewer side effects than current therapeutics. We have screened a series of nicotinic
compounds that vary in the distance between the pyridine and the cationic center, in steric bulk, and
in flexibility of the molecule. These compounds were screened using membrane binding and
synaptosomal function assays, or recordings from GH4C1 cells expressing hα7, to determine affinity,
potency and efficacy at four subtypes of nAChRs found in brain, α4β2*, α6β2*, α7 and α3β4*. In
addition, physiological assays in gain-of-function mutant mice were used to assess in vivo activity
at α4β2* and α6β2*-nAChRs. This approach has identified several compounds with agonist or partial
agonist activity that display improved selectivity for α6β2*-nAChR.
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Introduction
Dependence on nicotine partially underlies the difficulty encountered in smoking cessation.
Currently available smoking cessation aids (nicotine replacement, bupropion or varenicline
treatment) are helpful for a subset of the population, with variable relapse prevention (Lehrman
et al, 2007; De Biasi and Salas, 2008). There is a need for treatments with improved
effectiveness, relapse prevention, tolerability, and safety.
Nicotine elicits physiological and behavioral effects through actions as an agonist and/or
desensitizer at nicotinic acetylcholine receptors (nAChRs). nAChRs in brain exist as pentamers
made up of the α2-7, and β2-4 subunits. Some nAChRs are homomers (α7), but most are
heteromers (β2 or β4 in combination with α subunits) (Gotti et al, 2006). α4β2*-nAChRs, which
comprise the most widely expressed high-affinity subtypes, play a major role in modulating
the effects of smoked nicotine (Mameli-Engvall et al, 2006; Keath et al, 2007). Some α4β2*-
nAChRs are upregulated by chronic exposure to nicotine (Flores et al, 1992; McCallum et al,
2006; Nashmi et al 2007, Lester, 2009).
The α4α6β3β2 nAChR has the highest sensitivity for nicotine of any subtypes studied to date
(Salminen et al, 2007). In contrast to the widespread distribution of α4β2*-nAChR, α6β2*-
nAChRs have a restricted distribution, localized primarily to dopamine (DA) neurons,
noradrenergic neurons, and visual tracts (Whiteaker et al, 2000b; Champtiaux et al, 2002;
Champtiaux et al, 2003; Quik et al, 2003; Drenan et al, 2008). Both of these β2*-nAChR
subtypes are important regulators of DA release in the nucleus accumbens, which participates
in the rewarding effects of nicotine (Exley et al, 2008). α6β2*-nAChRs in mesoaccumbens
dopaminergic neurons may be necessary for nicotine self-administration (Pons et al, 2008).
Interestingly, α6β2*-nAChRs, despite their high sensitivity to nicotine, are upregulated at
comparatively high nicotine concentrations when expressed in HEK cells (Tumkosit et al,
2006), while they are downregulated following chronic nicotine treatment in rats and mice
(Lai et al, 2005; Perry et al, 2007; Perez et al, 2008).
Whole genome scans in humans have detected genetic associations between α6-nAChR subunit
genes and aspects of human smoking. The CHRNA6/B3 gene cluster has significant
associations with subjective responses to nicotine (Zeiger et al, 2008), tobacco dependence,
and number of quit attempts (Hoft et al, 2008). These associations may suggest that α6*-
nAChRs could be an important target for nicotine. nAChR subtype selective compounds will
become pharmacological tools to help identify how various subtypes affect the acquisition and
maintenance of addiction, as well as which subtypes are good targets for smoking cessation
therapy. Selective compounds may enable therapies to be tailored to individuals by combining
genetic association data with appropriate smoking cessation aids (Ho and Tyndale, 2007).
Based on knowledge gained using nAChR subunit null mutant mice and various selective
agonists and antagonists, we have devised a battery of assays to assess binding affinity,
functional potency and efficacy at four subtypes of nAChR (α4β2*, α6β2*, α7 and α3β4*).
Gain-of-function α4L9'A (Tapper et al, 2007) and α6L9'S (Drenan et al, 2008) mice have been
developed to evaluate selective activation of α4β2* or α6β2*-nAChR in vivo. We have assessed
the effects of structural modifications of nicotine that may improve selectivity for α4β2* and/
or α6β2*-nAChRs.
Methods
Materials
[125I]-α-bungarotoxin (α-Btx, specific activity 2000 Ci/mmol) was a product of GE Healthcare,
Little Chalfont, Buckinghamshire, UK. [125I]-epibatidine (2200Ci/mmol), [3H]dopamine (3,4-
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[ring-2,5,6-3H], 30-60 Ci/mmol), [3H]choline (methyl-3H, 60-90 Ci/mmol), and carrier-
free 86RbCl were purchased from Perkin Elmer Life Sciences, Boston, MA. α-Conotoxin MII
(α-CtxMII) and [125I]-α-CtxMII were obtained from J. Michael McIntosh, University of Utah,
Salt Lake City, UT. The following chemicals as well as all buffer components (Reagent Grade)
were products of Sigma-Aldrich (St Louis, MO): A-85380, atropine, aprotinin, bovine serum
albumin (BSA), α-cobratoxin, EDTA, EGTA, (±)-epibatidine, HEPES, (-)-nicotine tartrate,
leupeptin, nomifensine, pargyline, pepstatin A, PMSF, polyethylenimine and tetrodotoxin.
Compound synthesis
Compounds 1 (RJR2429, TC2429, (±)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane), 3
(TC1698, 2-(pyridine-3-yl)-1-azabicyclo[3.2.2]nonane), 6 (TC6951, (4S)-2-(5-
phenylpyridin-3-yl)quinuclidine) and 7 (TC2242, 4-(5-(quinuclidin-2-yl)pyridin-3-yloxy)
benzonitrile) were synthesized using previously published methods (Bhatti et al, 2008
compounds 3, 6, 26, and 29, respectively). Varenicline was synthesized by the methods of Coe
et al, (2005a) and Compound 8 (RJR2403, TC2403, (E)-N-methyl-4-(3-pyridinyl)-3-
butene-1-amine) following the methods of Bencherif et al, (1996). For other compounds:
Compound 2: (7-(pyridin-3-yl)-1-azabicyclo[2.2.1]heptane) Bencherif, Merouane; Miller,
Craig Harrison; Hawkins, Gregory D.; Bhatti, Balwinder S., preparation of pyridinyl subsituted
azabicyclic compounds for use in pharmaceutical compositions which effect dopamine release,
U.S. Pat. Appl. US2004220214. Compound 4: (1-aza-2-(3-pyridinyl)-tricyclo[3.3.1.13,7]
decane) Bencherif, Merouane; Lippiello, Patrick Michael; Crooks, Peter Anthony; Park, Haeil;
Bhatti, Balwinder Singh; Caldwell, William Scott; Dull, Gary Maurice, preparation of
azatricyclo[3.3.1.13,7]decanes and related compounds as nicotinic antagonists, PCT Int. Appl.
WO9951602. Compound 5: (2-(pyridin-3-ylmethyl)quinuclidine) Schmitt, Jeffrey Daniel;
Crooks, Peter Anthony; Dull, Gary Maurice, preparation of pyridyl-bridgehead derivatives and
their analogues, pharmaceutical compositions and methods for use, US Patent 6,432,975.
Compound 9: ((E)-N-methyl-5-(5-(phenylethynyl)pyridin-3-yl)pent-4-en-2-amine) was
prepared from known 3-bromo-5-(2-phenylethynyl)-pyridine (Agejas-Chicharro, Francisco
Javier; Dressman, Bruce Anthony; Gutierrez Sanfeliciano, Sonia; Henry, Steven Scott;
Martinez Perez, Jose Antonio; Massey, Steven Marc; Monn, James Allen; Zia-Ebrahimi,
Mohammad Sadegh, preparation of pyridines as mGlu5 receptor antagonists, PCT Int. Appl.
WO2005094822), according to the general methods cited in: Caldwell, William Scott; Dull,
Gary Maurice; Dobson, Grayland, 3-pyridinyl compounds. US 6,603,011. Compound 10
((1R,5S)-3-(5-bromopyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]oct-3-ene) was prepared
analogously to compounds reported previously (Gohlke et al, 2003). Compound 11 (2-((5-
chloropyridin-3-yloxy)methyl)quinuclidine) was prepared as described previously (Zhao et al,
2002).
Animals
All animal procedures were in accordance with the guidelines of the National Institutes of
Health. Mice of the C57BL/6J strain 60-90 days of age, used for this study were bred and
maintained at the Institute for Behavioral Genetics, University of Colorado, Boulder, CO. After
weaning at 25 days of age, same sex littermates were housed 5 to a cage with free access to
food (Teklad Rodent Diet, Harlan, Madison, WI) and water, with a 12-hr light/dark cycle at
22°C. Mice of the α4 subunit null mutant mice (originally from Dr. John Drago), were bred
and maintained as above and genotyped as previously described (Salminen et al, 2004). Animal
care and experimental procedures for these mice were in accordance with the guidelines and
approval of the Animal Care and Utilization Committee of the University of Colorado, Boulder,
CO.
Hypersensitive α4L9'A knock-in mice (Tapper et al, 2007) and α6L9'S (Drenan et al, 2008)
transgenic mice were bred and maintained at the California Institute of Technology, Pasadena,
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CA. Animal care and experimental procedures with these mice were approved by the California
Institute of Technology Animal Care and Use Committee.
Tissue preparation for binding studies
The methods of Marks et al (1998, 2006) were followed for preparation of brain membranes
in hypotonic buffer. These membrane preparations were stored as pellets under buffer at -70°
C or used immediately for [125I]-α-Btx and [125I]-epibatidine binding. The method of Salminen
et al (2005) was used for [125I]-α-CtxMII binding. Briefly, regions high in α-CtxMII binding
sites (olfactory tubercles (OT), striatum (ST) and superior colliculus (SC)) were pooled and
homogenized in hypertonic (2×) buffer (NaCl, 288 mM; KCl, 3 mM; CaCl2, 4 mM; MgSO4,
2 mM; HEPES, 40 mM; pH=7.5) and then incubated with PMSF (1 mM) at 22°C for 15 min
to inactivate serine proteases. After centrifugation (20,000 × g for 15 min at 4°C), the pellet
was resuspended in hypotonic buffer and re-centrifuged twice. The final pellet was resuspended
in distilled water and used without freezing.
[125I]-α-Bungarotoxin binding
A modification of previously published methods was used (Marks et al, 1998). Hippocampal
homogenate samples (∼50 μg protein) were incubated with 1 nM [125I]-α-Btx in 30 μl binding
buffer (NaCl, 144 mM; KCl, 1.5 mM; CaCl2, 2 mM; MgSO4, 1 mM; HEPES, 25 mM; pH 7.5)
supplemented with 0.1% BSA in 96-well plates modified to hold 1 ml capacity tubes. Various
concentrations of a compound to be tested for inhibition of [125I]-α-Btx binding were added
to triplicate wells; non-specific binding was determined from wells to which α-cobratoxin (100
nM) was added. After incubation for 2.5 hr at room temperature, samples were diluted with
0.5 ml binding buffer and incubated an additional 0.5 hr. This dilution step decreases non-
specific binding. Reaction was terminated by filtration onto glass fiber filters (MFS GB top
layer, Gelman A/E bottom layer, both soaked in binding buffer containing 0.5%
polyethylenimine) using an Inotech Cell Harvester (Inotech, Rockville, MD). Samples were
washed 6 times with ice-cold binding buffer and bound [125I]-α-Btx was determined by
counting at 60% efficiency in a 1450 MicroBeta Trilux scintillation counter after addition of
Optiphase SuperMix scintillation cocktail (150 μl/sample) (Perkin Elmer Life Sciences-Wallac
Oy, Turku, Finland).
[125I]-epibatidine binding
[125I]-epibatidine binding was determined using methods previously described (Marks et al,
1998; Whiteaker et al, 2000a) with minor modifications. As for [125I]-α-Btx binding various
concentrations of a compound to be tested for inhibition of were added to triplicate wells.
Briefly, for measurement inhibition of [125I]-epibatidine binding (corresponding to binding to
α4β2* sites) 100 pM [125I]-epibatidine was incubated with cortical membrane in 30 μl of
binding buffer for 2 hr at room temperature and then filtered onto a single thickness of
polyethylenimine –soaked GFA/E glass fiber filter (Gelman Sciences, Ann Arbor, MI) and
washed as for [125I]-α-Btx binding. For determining A85380-resistant [125I]-epibatidine
binding (corresponding to binding to α3β4* sites), membranes prepared from interpeduncular
nucleus (IPN) were assayed by including 10 nM A85380 (Sigma Chemical Co, St Louis, MO)
with 200 pM [125I]-epibatidine. For both procedures, 1mM (-)-nicotine tartrate was used to
determine nonspecific binding. Radioactivity was determined as for [125I]-α-Btx binding.
[125I]-α-CtxMII binding
The methods of Salminen et al (2005, 2007) were followed. Membrane samples (40-50 μg
protein) from pooled olfactory tubercle, striatum and superior colliculus were incubated with
0.5 nM [125I]-α-CtxMII in 30 μl binding buffer supplemented with BSA (0.1%), EDTA (5
mM), EGTA (5 mM), and the protease inhibitors, aprotinin, leupeptin and pepstatin A (10μg/
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ml each). Various concentrations of a compound to be tested for inhibition were added to
triplicate wells. Non-specific binding was determined from wells to which 1 nM epibatidine
was added. Binding reactions were incubated at 22°C for two hours, then diluted with 1 ml of
buffer containing 0.1% BSA and incubated 4 min longer. Reactions were terminated by
filtration onto a single sheet of GF/F filter paper (Whatman, Clifton, NJ) treated with 5% nonfat
dry milk for 30 min. Samples were washed four times with ice-cold buffer containing BSA
(0.1%). Bound ligand was determined by beta counting as above. It has been demonstrated that
this concentration of αCtxMII measures a6*-nAChR in mouse dopaminergic and visual tract
regions as no binding remains there in the α6 null mutant mouse (Champtiaux et al, 2002), and,
in addition, the α3 null mutation has no effect on αCtxMII binding in these regions (Whiteaker
et al, 2002).
Membrane binding data analysis
After subtraction of non-specific binding, inhibition of binding was analyzed by using a one-
site fit to the inhibition equation (B=Bo/(1+([I]/IC50) where B is ligand bound in the presence
of inhibitor at concentration [I], Bo is ligand bound in the absence of inhibitor (Whiteaker et
al., 2000a). Ki values were calculated from IC50 values using the equation (Ki=IC50/(1+(L/
KD)). Means ± sem from three to four experiments are reported.
Synaptosomal preparation
Regions of interest were dissected from fresh mouse brains and homogenized in ice-cold
isotonic sucrose (0.32 M) buffered with HEPES (5 mM, pH 7.5). The suspension was
centrifuged at 12,000 × g for 20 min and the pellet resuspended in the appropriate uptake buffer
(Salminen et al, 2007, Grady et al, 2001, Marks et al, 2007) and used immediately.
[3H]-Dopamine uptake and release
Release methods of Salminen et al (2004, 2007) were used. Briefly, the crude synaptosomal
pellet from striatal tissue was resuspended in dopamine uptake buffer (NaCl, 128 mM; KCl,
2.4 mM; CaCl2, 3.2 mM; MgSO4, 1.2 mM; KH2PO4, 1.2 mM; HEPES, 25 mM; pH 7.5;
glucose, 10 mM; ascorbic acid, 1 mM; pargyline, 0.01 mM) at 1.6 ml/tissue from one mouse.
Synaptosomes were incubated at 37°C for 10 min before addition of [3H]DA at 1 μCi for every
0.2 ml (∼100 nM), and the incubation continued for another 5 min. Subsequently, aliquots of
the suspension (80 μl) were distributed onto filters and perfused at room temperature with
uptake buffer containing 0.1% BSA, nomifensine (1 μM), to prevent re-uptake of dopamine,
and atropine (1 μM), to prevent any possible activation of muscarinic acetylcholine receptors,
at 0.7 ml/min for 10 min before stimulation with agonist for 20 s. Selected aliquots were
perfused with α-CtxMII (50nM) for the last 5 min of the wash period, immediately before
stimulation. This concentration of α-CtxMII is sufficient to inhibit all α6β2*-nAChR forms
present in mouse striatum (Salminen et al, 2007). Fractions (∼0.1 ml) were collected every 10s
into 96-well plates using a Gilson F204 fraction collector (Middleton WI) for 3 min after the
10 min washout. After addition of 0.15 ml of Optiphase SuperMix scintillation cocktail,
radioactivity was determined in a 1450 MicroBeta Trilux counter (Perkin Elmer Life Sciences
– Wallac Oy, Turku, Finland).
[3H]-ACh uptake and release
Release methods of Grady et al (2001) were followed with minor modifications. Briefly, the
crude synaptosomal pellet from IPN tissue was resuspended in choline uptake buffer (NaCl,
128 mM; KCl, 2.4 mM; CaCl2, 3.2 mM; MgSO4, 1.2 mM; KH2PO4, 1.2 mM; HEPES, 25 mM;
pH 7.5; glucose, 10 mM; 0.1%BSA) at 0.1 ml/mouse. After the addition of [3H]choline at
2μCi for every 0.1 ml (∼300 nM), the suspension was incubated at 37°C for 30 min. Then,
aliquots (20 μl) were distributed onto filters on the perfusion system at room temperature and
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perfused for 10 min at 0.7 ml/min with choline uptake buffer containing atropine (1 μM) before
stimulation by agonist for 20 s. Collection of fractions and determination of radioactivity were
as for dopamine release.
86Rb+ efflux
Nicotine-stimulated 86Rb+ efflux from synaptosomes was investigated using the methods of
Marks et al. (1999, 2007) with minor modifications. Briefly, Crude synaptosomes prepared
from thalamus were resuspended in uptake buffer (NaCl, 140 mM; KCl, 1.5 mM; CaCl2, 2
mM; MgSO4, 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 mM) (350 μl/mouse thalamus).
Aliquots (25 μl) of the suspension were added to 10μl of uptake buffer containing 4
μCi 86Rb+ and incubated at room temperature for 30 min. The whole sample was then collected
onto filter paper (Type AE, Gelman, Ann Arbor, MI), rinsed once with 0.5 ml of uptake buffer,
transferred to the perfusion apparatus, and perfused with buffer (NaCl, 135 mM;CsCl, 5 mM;
KCl, 1.5 mM; CaCl2, 2 mM; MgSO4, 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 mM;
tetrodotoxin, 50 nM; atropine 1 μM; BSA 0.1%) at 2.5 ml/min for 5 min before data collection
began. Stimulation by agonist was for 5s. Effluent was pumped through a 200 μl Cherenkov
cell in a β-Ram HPLC detector (IN/US Systems, Tampa, FL) to continuously monitor
radioactivity.
Synaptosomal function data analysis
All synaptosomal function assays were calculated as counts exceeding basal release determined
from samples immediately preceding and following stimulation (Grady et al 2001; Salminen
et al, 2004; Marks et al, 1999). Stimulated release was normalized to baseline to give units of
release as a fraction of baseline. Fractions significantly over baseline for each perfusion were
summed. EC50 values were calculated by fitting data (means of three to four experiments) to
the Hill equation, or two Michaelis-Menten equations when data were biphasic. IC50 values
were calculated from the inhibition equation (release=Ro/(1+[An]/IC50, where Ro=uninhibited
release and [An] is the concentration of antagonist) using the non-linear least squares algorithm
in SigmaPlot 5.0 (Jandel Scientific, San Rafael, CA). The errors for the EC50, IC50 and efficacy
(as maximum activity expressed as % nicotine) are errors generated by the least-squares
computational algorithm in SigmaPlot termed “sem”. This “sem” reflects error of the curve fit
for the entire data set rather than an sem calculated from independent determinations of these
parameters.
Current recordings from GH4C1 cells
GH4C1, a stable cell line expressing the hα7-nAChR subunit, was used to measure whole-cell
currents (see Dunlop et al., 2007 and Supplementary Figure 1). After removal from the
incubator, cells were washed twice with extracellular recording medium (NaCl, 130 mM; KCl,
5 mM;CaCl2, 2 mM; MgCl2, 2mM; glucose, 25 mM; HEPES, 10 mM, pH 7.4) and placed into
a 48 channel Dynaflow chip (Cellectricon, Inc). Chips were placed on the Dynaflow stage of
an inverted Zeiss microscope at room temperature. Borosilicate electrodes were filled with:
Tris-phosphate dibasic, 110 mM; Tris-base, 28 mM; EGTA, 11 mM; MgCl2, 2 mM; CaCl2,
0.5 mM; NaATP 4 mM, pH 7.25 and had resistance of 2-5 MΩ. Currents were recorded with
Axopatch 700A amplifier, filtered at 1 kHz, and sampled at 5 kHz. On average, the whole-cell
recording stabilized within < 5 min. Responses were evoked by moving the cell in front of the
agonist-containing channel for 1 s, and 30 s washout periods were used between applications.
With this method, solution exchange occurs within 10 msec.
Electrophysiological data analysis
Data were fit to a single Hill equation using Prism 5 software. Data are expressed as mean ±
SEM with of 4 independent measurements. Measurements of steady state current would result
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in EC50 values shifted to the left by 10-fold or more approaching Ki values for binding (see
Supplemental Figure 1). We used peak current measurements for data presented in this paper
as most likely to represent activation EC50 values comparable to those measured in our
synaptosomal release and efflux assays.
Hypothermia and locomotor activity measurements
The methods of Tapper et al (2007) were followed to measure the hypothermic effect of selected
compounds. α4L9'A knock-in mice were used to isolate effects on α4β2*-nAChR subtypes as,
in these mice, the dose required to elicit nicotine-induced hypothermia (0.01 mg/kg) is below
doses that affect other subtypes as shown by a lack of effect of this dose in wild-type mice
(Tapper et al, 2007). Briefly, mice were injected ip with saline, low dose nicotine (0.01 mg/
kg), selected compound (agonists), or selected compound (antagonist) followed by low dose
nicotine 8 min later, and body temperature was recorded in the home cage via previously
implanted telemetry probes (Vital View PDT-4000 from Respironics). The maximum change
in temperature within 40 min of injection was recorded.
α6L9'S transgenic mice were used to isolate effects on α6β2*-nAChR subtypes with
measurements of locomotor effects. Doses of nicotine (0.1 mg/kg) that do not affect wild-type
mice have marked effects in these transgenic α6 mice (Drenan et al (2008). Briefly, baseline
horizontal locomotor activity was measured in an infrared photobeam activity cage (San Diego
Instruments, San Diego, CA) for 8 min before injection of either saline, low dose nicotine (0.1
mg/kg), selected compound (agonist), or selected compound (antagonist) followed by low dose
nicotine 8 min later. Activity was then measured for an additional 30 min.
Results
This report incorporates two major themes: 1) We describe a battery of assays to assess the
selectivity and activity of potential nicotinic compounds in vitro and in vivo. 2) We apply these
assays to evaluate a series of potential nicotinic compounds in order to provide new data on
nAChR subtype selectivity and to establish a structure-activity relationship (SAR) framework
for assessing improved selectivity. The structures of the compounds tested in the current study
are shown in Figure 1.
Binding Assays
Figure 2 presents inhibition profiles using four different membrane binding assays with
Compound 1 as the test compound. Panel A shows the inhibition of high affinity [125I]-
epibatidine binding to mouse cortical membranes, an assay that measures almost exclusively
the α4β2*-nAChR. (Marks et al, 2006). The Ki for Compound 1 at this site is 0.46 nM. Panel
B shows the inhibition of high-affinity [125I]-epibatidine binding to mouse IPN membranes in
the presence of sufficient A-85380 to block the α4β2* sites; the site defined by the this binding
is largely α3β4*-nAChR in this brain region (Whiteaker et al, 2000a) and has a Ki for
Compound 1 of 4.4 nM. Panel C shows inhibition by Compound 1 of [125I]-α-Btx binding, a
selective ligand for α7-nAChR, in mouse hippocampal membranes (Marks et al, 1998). The
Ki for Compound 1 at this site is 7.6 nM. Panel D represents inhibition by Compound 1 of
[125I]-α-CtxMII binding, a selective ligand for α3β2* and α6β2* to mouse membranes from
combined regions, striatum (ST), olfactory tubercle (OT), and superior colliculus (SC), which
are all relatively high in the α6β2*-nAChR subtype and low in α3β2* (Salminen et al, 2005).
The Ki for Compound 1 at this site is 1.14 nM.
Functional Assays
The affinity measurements above provide some information on the interaction of ligands with
these receptor subtypes, but give no indication of their functional activity. Figure 3 presents
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functional data from appropriate biochemical (Figure 3A, B, C) or electrophysiological (Figure
3D) assays for each of the four nAChR subtypes, again using Compound 1 for illustration. For
the data in panels A, B and C, functional responses were measured using mouse brain
synaptosomes. The activity of a concentration of nicotine, maximal for each assay and assessed
in the same assays, is also shown and has been used to estimate relative efficacy. EC50 values
were determined by fits to the Hill equation or, for biphasic curves, to two Michaelis-Menton
equations.
Panel A of Figure 3 shows 86Rb+ efflux stimulated from mouse thalamic synaptosomes by the
indicated concentrations of Compound 1. A biphasic concentration-response curve was
observed. Previous data show that the higher agonist-sensitivity (HS) component also has
higher sensitivity to block by DHβE (2 μM) (Marks et al, 1999). We therefore isolated the
DHβE-sensitive portion by subtracting the responses in the presence of DHβE from the total
responses; the inset shows the calculated HS α4β2* responses. The EC50 value for this HS
form is assessed from either this plot of the DHβE-sensitive component or by the higher-affinity
portion of the biphasic plot. The lower sensitivity (LS) form is assessed from the curve with
DHβE present and by the component of the concentration-response curve elicited by higher
agonist concentrations. Compound 1 is a partial agonist at both the HS and LS forms with
efficacies of 31% and 29% relative to the test concentrations of nicotine, respectively.
Corresponding EC50 values are 0.043 μM and 5.5 μM, much lower than those reported for
nicotine [1.4 μM and 130 μM (Marks et al., 1999)].
Panel B of Figure 3 shows results of the Compound 1 stimulated release of [3H]-DA from
mouse striatal synaptosomes. The three plots represent total release mediated by a combination
of various β2*-subtypes, the portion resistant to inhibition by 50 nM α-CtxMII (virtually all
HS form of α4β2* as the highest concentration assessed was 0.3 μM), and the difference which
represents the portion sensitive to α-CtxMII (α6β2*) (Champtiaux et al, 2002,2003;Salminen
et al 2004). Compound 1 is a partial agonist for the α-CtxMII-resistant (α4β2*) component
with an efficacy 28% that of nicotine and an EC50 value of 0.034 μM. In contrast, Compound
1 is a full agonist at the α-CtxMII-sensitive (α6β2*) component with an efficacy 109% that of
nicotine and an EC50 value of 0.0074 μM. The EC50 values for both components are
considerably lower than the corresponding values for nicotine [1.6 μM and 0.77 μM,
respectively (Salminen et al., 2004)].
Panel C of Figure 4 shows the Compound 1-stimulated release of [3H]-ACh from mouse IPN
synaptosomes, an assay that measures function of the α3β4*-nAChR subtype (Grady et al,
2001). Compound 1 is a full agonist in this assay with a maximal response 106% that of nicotine
and an EC50 value of 0.43 μM, which is significantly lower than the EC50 value for nicotine
(64 μM, Grady et al., 2001) but substantially higher than that for HS α4β2*- or α6β2*-nAChR
mediated responses.
Responses mediated by α7-nAChRs are more reliably measured by electrophysiology in
transfected cell lines than by biochemical assays in mouse brain synaptosomes. Panel D of
Figure 4 shows data for peak whole-cell current evoked from patch-clamped GH4C1 cells
expressing rat α7-nAChR. These data are expressed as % maximal ACh response. In
comparison to ACh, nicotine was a full agonist for this activity (data not shown; 100% max at
200 μM). Compound 1 is also a nearly full agonist in this assay with a maximal response 89%
that of nicotine. The EC50 value of 0.66 μM was the highest of the four responses measured.
Screening of compounds
Each of the compounds represented in Figure 1 was assayed for each of the measures illustrated
in Figures 2 and 3, respectively. Ki values for inhibition of binding of these compounds are
compiled in Table 1. Figure 4A presents these affinity values on log molar scales, in a plot that
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emphasizes each compound's rank order for each of the four subtypes. Most of the compounds
evaluated had higher affinity for the α4β2*-nAChRs relative to the other subtypes, as is typical
for most reported nicotinic ligands. For function (assays in Figure 3), all compounds were
initially screened for agonist activity. Several compounds had no agonist activity; and were
tested for antagonist activity as measured by the inhibition of nicotine-stimulated responses,
and Ki values determined. The data on functional activity are compiled in Tables 2 and 3 and
also represented graphically, as potency values (EC50 or Ki) in Figure 4B and efficacy relative
to nicotine (as a percentage) in Figure 4C. For this representation, a fully efficacious compound
has 100% maximum activity as compared to the activity of nicotine, while an antagonist that
fully blocks the effect of nicotine is plotted at -100%. Several compounds have partial activity
(between 0 and 100) while a few are more efficacious than nicotine (over 100). A value of 0
indicates that no agonist or antagonist activity was detected. In addition to compounds 1-11,
values for a number of common nicotinic compounds as well as varenicline are presented for
comparison in Figures 4A, B and C (see also Tables 1, 2, and 3 for nicotine and varenicline).
α4β2*-nAChR-Mediated Responses
From the assays shown in panels A and B of Figure 3, we can measure potency and efficacy
relative to nicotine for activity mediated by the α4β2*-subtype by two independent methods:
HS 86Rb+ efflux and α-CtxMII-resistant [3H]-DA release. These two measures of α4β2*
potency showed good agreement: a scatterplot on logarithmic axes has a regression slope of
0.98 ± 0.08 and a correlation coefficient of 0.96 (Figure 5A). The mean ratio of the points (0.97
± 0.14) does not differ from 1. The accuracy of these methods with a limited number of
replicates appears adequate to ascertain functional potency within a ∼ 3 to 10-fold difference.
For the purpose of identifying a compound useful for differentially activating or inhibiting
subtypes of nAChRs, this level of accuracy should suffice.
Functional responses mediated by α4β2*-nAChR measured within the series of compounds
shown in Figure 1 reveal that only four of the eleven compounds (including Compound 1) are
agonists (see Figure 4C). Compound 8 was unique in that it had higher efficacy than nicotine
at α4β2*-elicited [3H]-DA release (150%) and at α4β2*-nAChR mediated 86Rb+ efflux
(254%), but with relatively high EC50 values (14.8 and 14.6 μM, respectively, see Figure 4B
and supplementary tables). Compound 2 is a partial agonist (64% and 21%), albeit much less
potent than Compound 1 (EC50 1.04 μM and 0.32 μM). Finally, Compound 10 was a partial
agonist (37% efficacy for α-CtxMII-resistant [3H]-DA release and 63% for 86Rb+ efflux), but
intermediate potency (0.18 μM and 0.06 μM) compared to Compound 1 and Compound 2.
α6β2*-nAChR-Mediated Responses
Functional responses mediated by α6β2*-nAChR, as the α-CtxMII-sensitive component of
[3H]-DA release, measured within the series of compounds shown in Figure 1 reveal that only
three of the eleven compounds (including Compound 1) are agonists. Compound 10 is a potent
(EC50 = 0.12 μM) partial agonist with 56% of the efficacy of nicotine. Compound 2 is a potent
full agonist with an EC50 value of 0.050 μM. In contrast to the α4β2*-mediated responses
where Compound 8 is more efficacious than nicotine, Compound 8 displays no measurable
activity on α-CtxMII-sensitive DA release. Interestingly, α6β2*-nAChR appear to be activated
by lower concentrations of many agonists than α4β2*-nAChR (see Figure 4B and Table 2)
even though these same agonists have higher affinity for α4β2* sites in binding assays (see
Figure 4A and Table 1). Comparing data in Figure 4A and 4B, this pattern, where a compound
has higher affinity for α4β2*-nAChR than α6β2*-nAChR for binding, but lower or equal
potency for activation, is seen for the agonists, nicotine, ACh, cytisine, epibatidine, A85380,
varenicline and compounds 1, 2 and 10. In contrast, antagonists that have highest affinity for
α4β2*-nAChR also have highest potency for inhibition at that subtype. In addition, compound
8 has no functional activity at α6β2*-nAChR, so it cannot be compared. It seemed possible
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that for α6β2*-nAChR, measurements of inhibition of binding of an antagonist ([125I]-
αCtxMII) might differ from inhibition of binding of an agonist ([125I]-epibatidine), possibly
explaining the relatively lower affinities measured for α6β2* sites using αCtxMII, an
antagonist. Therefore, we compared data collected by two independent methods for binding to
α6β2*-nAChR sites to check accuracy of the results of this screening method. The first method,
illustrated in Figure 2D, is inhibition of [125I]-αCtxMII binding; the alternate method, using a
similar membrane preparation from mice with the α4 subunit null mutation, assessed inhibition
of high affinity [125I]-epibatidine binding to the remaining, presumably α6β2*, nAChRs. In
ST, ∼10% of high affinity [125I]-epibatidine binding remains in the α4 subunit null mouse; and
in OT, ∼8% remains (Marks et al, 2007). In addition, the α4 subunit null mouse has ∼50%
lower [125I]-α-CtxMII binding in these regions, although the affinity for α-CtxMII is
unchanged (Salminen et al, 2005,2007). In a comparison of Ki values determined by the two
methods (see Table 1 for values ± sem for both methods for those compounds assayed both
ways), the regression slope on logarithmic axes was 1.08 ± 0.08 with a correlation coefficient
of 0.96 (Figure 5B). Furthermore, the mean ratio of the Ki values determined by the two
methods (0.88 ± 0.13) is not significantly different from 1. Therefore, we conclude that the
lower affinity values measured for α6β2*-nAChR sites are not an artifact of measuring binding
affinities with [125I]-α-CtxMII rather than with [125I]-epibatidine, since measurements of
α6β2* binding affinity for a number of compounds using α4 subunit null mutant membranes
with [125I]-epibatidine resulted in the same Ki values as those measured with [125I]-α-CtxMII
(Figure 5B).
α7-nAChR-Mediated Responses
All of the compounds tested, except Compound 9 which was inactive, showed at least some
agonist activity for α7-nAChR-mediated function (Figure 4C and Tables 3). Compound 2 is a
full agonist. However, like Compound 1, the EC50 value for this compound (4.97 μM) was
significantly higher than the corresponding value observed for α4β2* (0.68 μM) and α6β2*
(0.05 μM) responses. Compounds 3 and 5 are full agonists with EC50 values of 0.15 and 4.1
μM, respectively. Partial agonist activity was noted for the remaining compounds with
efficacies ranging from 17% to 63%. In general, EC50 values for α7-nAChR activation were
markedly higher than those for α4β2*- and α6β2*-nAChR mediated responses, although the
ratio of EC50 to Ki value (77 ± 14, n=11) was similar to that for α4β2*-nAChR.
α3β4*-nAChR-Mediated Responses
α3β4*-nAChR mediated responses were measured by [3H]-ACh release from IPN
synaptosomes. Nine of the 11 compounds tested show some agonist activity (Figure 4C and
Tables 3). Compounds 1, 2, 3, 4, 5 and 7 were full or nearly full agonists, while Compounds
8, 10 and 11 were partial agonists. The EC50 for Compound 8 was a very high 218 μM. Both
Compound 6 and Compound 9 were full antagonists, with Compound 6 exhibiting high potency
(KI = 0.66 μM).
Evaluation of effect of structural differences on interaction with nAChR subtypes
Compound 8 and Compound 9 are both classified as metanicotines, analogs of nicotine in
which the pyrrolidine ring is opened and a double bond introduced adjacent to the pyridine.
This results in a more flexible molecule than nicotine and increases the distance from the
cationic center to the hydrogen bond acceptor. Relative to nicotine, Compound 8 possesses
decreased affinity at α4β2*, α7 and α6β2* subtypes. Like nicotine, Compound 8 displayed
selectivity for the α4β2* subtype, consistent with previous reports (Bencherif et al, 1996). In
terms of functional activity, Compound 8 is even more efficacious than nicotine at α4β2*, but
displays no measurable activity at α6β2* and weak partial activity at α3β4* and α7-subtypes.
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Introduction of a phenyl ring at the 5′ position of the pyridine (Compound 9) through an alkyne
linker further reduced binding affinity across subtypes, but maintained selectivity for the
α4β2* sites. This modification also resulted in antagonism at all subtypes, though antagonism
at α6β2* was partial (∼50% inhibition). It remains to be seen whether this compound selectively
inhibits one of the complex α6β2*-nAChR subtypes (i.e., α6* receptors with or without an
α4 subunit incorporated).
Constraining the basic structural elements of Compound 8 (pyridine, alkene, aminomethyl)
into an azabicyclo[3.2.1]octene ring and adding a 5′-bromo substituent results in Compound
10. This conformational constraint increased the binding affinity by more than an order of
magnitude at all four subtypes, while still retaining modest selectivity for α4β2*. These
modifications also returned partial agonist activity at all subtypes measured. In fact, Compound
10 appears unique among the compounds studied here in having partial agonist activity across
all subtypes. Relative to Compound 8, Compound 10 exhibited significantly reduced efficacy
(25% of Compound 8) at both α-CtxMII-resistant DA release and α4β2*-mediated 86Rb+
efflux, but increased the potency 83- and 250-fold, respectively. Compound 10 demonstrated
considerable potency-based functional selectivity (∼100-fold) for the β2* (both α4 and α6)
containing subtypes over both α7 and α3β4*-subtypes. This selectivity might be expected to
reduce side effect liabilities relative to less selective ligands, particularly with regard to the
α3β4* subtype.
Replacement of the pyrrolidine ring of nicotine by the azabicyclo[2.2.2]octane (quinuclidine)
ring system (Compound 1) has multiple steric and electronic effects. The basicity of the cationic
center nitrogen is greatly enhanced, steric bulk around the cationic center is also greatly
increased, and the resulting molecule is considerably more rigid. These structural modifications
conferred enhanced binding affinity across all four receptor subtypes (∼10-40-fold increase).
With respect to efficacy and potency, Compound 1 is a partial agonist at both DA release (28%)
and Rb efflux (31%) measures of α4β2* function, but is very potent (EC50 0.034 μM for [3H]–
DA release, 0.043 μM for 86Rb+ efflux). Although the efficacy for α4β2* function by
Compound 1 is fairly low, this compound is a potent, full agonist for the component of
dopamine release mediated by α6β2* (109%, 0.0074 μM EC50). Compound 1 is highly
efficacious at the α3β4* and α7 subtypes (106% and 89%, respectively), but the EC50 values
(0.43 μM and 0.66 μM) are 10- to 100-fold higher than those for α4β2* and α6β2*-receptors.
By this measure, Compound 1 represents a functionally highly selective and efficacious
α6β2* agonist, though less selective by binding affinity measures.
The Compound 1 template was further elaborated at the 5′-pyridine position, to explore the
effects of aromatic bulk across the various receptor subtypes. Introduction of a phenyl ring
gave Compound 6, which exhibited decreased affinity for all four subtypes (Figure 4A and
Table 1). This decrease was modest (∼4-5-fold) for α4β2* and for α6β2*, but approximately
10-fold for α3β4*. The largest effect was noted for the α7 subtype, where affinity decreased
approximately 50-fold. The presence of the phenyl ring markedly affects functional activity
for several subtypes. Agonism was abolished at α4β2* or α6β2*, resulting in full, potent
antagonists. Compound 6 was also a full antagonist at α3β4*, but retained weak partial agonist
activity at α7 (18% EMax, 29 μM).
Extension of the 5′-position of Compound 1 with a 4-cyanophenoxy group provided Compound
7. This modification was quite well tolerated, retaining affinity comparable to that of the parent
Compound 1 for α4β2*, α6β2* and α7 subtypes, while decreasing affinity for the α3β4*
subtype by ∼10-fold. Like Compound 6, Compound 7 was a potent, full antagonist at α4β2*
and α6β2*. In fact, at α6β2* it was 40 times more potent than Compound 6. At α3β4* and α7,
the agonism profile more closely matched that of parent Compound 1, with full agonism at
α3β4* and partial at α7 (103% and 63%, respectively).
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Compound 5 and Compound 11 both retain the azabicyclo[2.2.2]octane ring of Compound 1,
but extend the pyridine group away from the basic nitrogen by a carbon or one carbon and one
oxygen atom, respectively. For Compound 5, the affinity was markedly decreased at all four
sites relative to Compound 1. The smallest change was observed for α7 (∼ 7-fold reduction),
while the α6β2* affinity decreased 80-fold. Compound 5 was a full antagonist at both α4β2*
and α6β2*-subtypes while maintaining full but less potent agonism at the α7 and α3β4*-
subtypes.
Additional extension of the methylene spacer by introduction of an oxygen atom and
translocating the spacer from the 2- to the 3- position on the quinuclidine yielded Compound
11 (which also has a 5′-Cl substitution in the pyridine ring). This further reduced affinity at all
four binding sites compared to Compound 5 (further 7- to 26-fold decrease). Similar to
Compound 5, full antagonism was observed at α4β2* and α6β2*, but potency was reduced
somewhat (16 and 2-fold, respectively). Surprisingly, a loss of agonism was observed at both
α7 and, more profoundly, α3β4* (Emax =31% and 8%, respectively). We cannot yet distinguish
the individual contributions of the 5-chloro substituent and the oxygen atom relative to the
increase in linker length alone, because the corresponding analogs were not available for
evaluation.
A one-carbon reduction in the bridging ethyl group of Compound 1 afforded the corresponding
1-azabicyclo[2.1.1]heptane (Compound 2). This resulted in markedly reduced binding affinity
for all four sites: ∼20-fold at α4β2*, α6β2* and α3β4*. Compound 2 did retain agonism at the
α6β2*, α7 and α3β4* subtypes as well as partial agonism at α4β2*, but was less potent than
Compound 1. Compound 2 also retained the full, potent agonism at α6β2* observed for
Compound 1 (114%, 0.050 μM), and the α6β2* functional selectivity is even higher due to the
reduced potency at α4β2*-subtype. A corresponding one-carbon increase in the bridging ethyl
group of Compound 1 afforded the corresponding 1-azabicyclo[3.2.2]nonane (Compound 3).
The affinity of Compound 3 resembled Compound 1; however, a notable 6-fold reduction in
affinity at the α3β4* site was achieved. The functional profile again resembled that observed
for the previously discussed analogs: a shift to antagonism at α4β2* and α6β2*, but retention
of α7 and α3β4* full agonism. In α6β2* [3H]-DA release, assays, only partial antagonism was
observed for Compound 3 (-71% Imax, 0.052 μM). One possible explanation for this
observation is selective inhibition of only one of the complex α6β2*-nAChR subtypes.
Finally, addition of two carbons to the Compound 1 ring system and altering the bridge
connectivity produced the highly constrained 1-azatricyclo[3.3.1.13,7]decane (aza-
adamantane), Compound 4. The binding affinity of Compound 4 was markedly reduced across
all subtypes, quite similar to the profile observed for Compound 2. The increase in steric bulk
surrounding the cationic center apparently resulted in full antagonism of α4β2*. At the α6β2*
subtypes, full antagonism was also observed, in contrast to the partial antagonism of Compound
3. Compound 4 exhibited a reduction of efficacy and large loss of potency at α3β4* and α7
(88%, 34 μM and 27%, 8.5 μM, respectively). This efficacy-potency shift again affords a
selective antagonist. The potency is highest for α4β2* (0.069 μM), with some antagonism for
α6β2* (0.57 μM), and less at α7 (34 μM) and α3β4* (8.5 μM).
Evaluation of Effects of Compounds in vivo
In order to assess the effects of selected compounds in vivo, we used mice with gain-of-function
mutations in α4 and α6 subunits. Mice with the α4L9'A or α6L9'S mutations respond to very
low concentrations of nicotine that have no measurable effect in wildtype mice and allow an
assessment of whether a compound is bioavailable as well as whether it activates or inhibits a
specific subtype of nAChR in vivo. For the α4L9'A mice, injection of 0.03 mg/kg nicotine
produces a 3°C temperature decrease, while this dose elicits no hypothermia in wild type mice
(Tapper et al, 2007). Thus this procedure measures an effect of nicotine restricted to the α4*-
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nAChRs. For the α6L9'S mice, low doses of nicotine (0.02-0.15 mg/kg ip) result in locomotor
activation (∼350% of saline activity for 0.15 mg/kg nicotine), while in wild type there is no
effect of these doses of nicotine, and, in fact, higher doses (0.5-2.0 mg/kg ip) in wildtype mice
as well as doses over 1 mg/kg in α6L9'S mice produce locomotor suppression (Drenan et al,
2008). In addition, the α6L9'S-gain-of-function mice have the same temperature depression
responses as wild type mice (unpublished data; see Tapper et al, 2007 for wild type), <1° C
temperature decrease with a dose of 0.1 mg/kg nicotine. Thus, this measurement isolates an
α6*-nAChR-mediated physiological effect. Representative experiments using Compound 1,
identified as a partial agonist at α4β2* and a full agonist at α6β2* in the in vitro assays are
shown in Figure 6. Compound 1 proved active in vivo and stimulated both α4L9'A* nAChRs,
with 0.03 mg/kg inducing ∼8° temperature drop and α6L9'S*-nAChRs where 0.01 mg/kg
resulted in ∼290% increase in activity over saline. Subsequently, the agonists Compounds 2,
8 and 10 were evaluated for their ability to elicit hypothermia or locomotor activation in
α4L9'A and α6L9'S mice. As shown in Table 4, each of these compounds elicited responses
in both mutant mice expressing hyperactive nAChR. Compounds 3, 4 and 7, which were
identified as antagonists, blocked the effects of 0.1 mg/kg nicotine in vivo. Data for nicotine
and varenicline are provided for comparison in Table 4.
Discussion
The CNS nAChRs have various roles in normal brain function. These receptors are activated
by the natural neurotransmitter, acetylcholine, and their activity may also be modified by the
presence of nicotine (Perez et al, 2008). Nicotine from tobacco smoking occupies a large
fraction of the α4β2*-nAChR (Brody et al., 2008). Such data are not available for the α6β2*-
nAChRs, but if nicotine occupies a lower percentage of these receptors, or desensitizes them
less readily, nicotine use could produce an altered balance between GABAergic and
dopaminergic function. To better understand the role of the α6β2* and to define the optimal
profile for therapeutics targeting nicotine addiction as well as other disorders that are potential
targets for nicotinic receptor-based therapy, selective ligands are necessary. The lack of
available data around α6β2* SAR and limited structure-function data for other subtypes led us
to prepare and/or characterize a number of known and novel ligands across various nicotinic
receptor subtypes.
Our data show that commonly studied nicotinic agonists including nicotine, acetylcholine,
cytisine and A-85380, bind to α4β2*-nAChR subtype with higher affinity than to α6β2*, and,
generally, had lower affinity at both the α7 and α3β4*-subtypes (see Figure 4A and Table 1).
However functional measurements (Figure 4B and Table 2) reveal that several agonists activate
α6β2*-nAChR at lower concentrations than α4β2*-nAChR. Thus, the relationship between
binding affinity and functional potency differed markedly between the α6β2*- and α4β2*-
nAChRs (see also Salminen et al, 2005). Presumably this disparity arises from inherent
differences in relationships among binding, activation and desensitization. Further study will
be required to understand this topic. Furthermore the α6β2*-subtype actually comprises several
receptors, including α4α6β2β3, which is activated by lower concentrations of nicotine than the
α6β3β2 or the α4(non-α6)β2*-nAChR (Salminen et al, 2007).
Varenicline (currently marketed as a smoking cessation aid) was also evaluated in our assays.
We found that varenicline is a partial agonist at both α4β2* and α6β2*-nAChRs, but a full
agonist at both α7 and α3β4* subtypes; these conclusions (for α4β2*, α7 and α3β4* subtypes)
agree with data from oocyte-expressed nAChRs (Mihalek et al., 2006) and from rat brain slices
(Rollema et al, 2007). Note that the structurally-related compound cytisine, is also a partial
agonist at α4β2*-nAChRs (37%); however, cytisine is more efficacious at α6β2* (71%)
(Salminen et al, 2004). For varenicline, efficacy is not significantly different between these
subtypes for this screen (26 ± 2% and 39 ± 17%, respectively). We found an ∼8-fold ratio of
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EC50 values between α7 and α4β2*-subtypes, the same as previously reported for oocyte-
expressed receptors (Mihalek et al, 2006). According to our data in mouse tissue, varenicline
is somewhat selective for α4β2*-nAChR when assessed with binding affinity (2-fold over
α6β2*, 9-fold over α7 and 24-fold over α3β4*) though considerably less selective than reported
for rat brain α4β2* compared to α7 in IMR32 cells (Rollema et al, 2007). Our data on
varenicline generally agree with published data from other laboratories (see Supplementary
Table 1 for a compilation of data with species, method and source) in finding that it is a partial
agonist at α4β2*, with higher efficacy at α7 and α3β4*-nAChR. There may be some species
or methods differences in these data.
The structures of a series of nicotine-related compounds that were evaluated in this study are
shown in Figure 1. Within this series, the basic pharmacophoric elements of nicotine (cationic
center, hydrogen bond acceptor and aromatic ring) were retained, but elaborated into a set of
chemically diverse analogs: 1) the distance from the pyridine to the cationic center is varied,
2) steric bulk of the molecule (particularly the region around the cationic center) is explored,
and 3) flexibility is varied from compounds with many degrees of freedom (the metanicotines
Compounds 8 and 9) to highly constrained (3-pyridinyl-azatricyclo[3.3.1.13,7]decane)
Compound 4. Some data on affinity, potency and efficacy have been previously published for
certain of these compounds and a comparison of these values, along with species and
references, is presented in Supplementary Table 2. As with varenicline, some differences may
result from methods or species used. Despite the wide variety of techniques and species, there
is considerable agreement where comparable data exist.
The data presented here suggested several observations about the role of structure in affinity
and efficacy. Generally, constraining the cationic nitrogen into certain ring variations enhances
affinity across all subtypes relative to the open-chain metanicotine. Increasing the
conformational constraint further by capturing the cationic center into bicyclic ring systems
further enhances affinity. This affinity enhancement is illustrated clearly in the progression
from Compound 8 to nicotine to Compound 10 to Compound 3 and finally Compound 1, where
the Ki values decrease between one and three orders of magnitude. Binding affinities for the
α6β2* and α7 receptors are most affected by these structural changes. (Compound 2 and
Compound 4 are excluded from this comparison since they represent more significant changes
in pyridine-nitrogen orientation and steric effects, respectively.) It is not clear what factors are
responsible for this affinity shift, since these structural changes alter the character of the
molecule in several ways. For example, the cationic center is changed from secondary to
tertiary, basicity is increased, lone nitrogen electron pair orientation altered, steric bulk is added
(which can be both repulsive or provide positive hydrophobic interactions), and bond distances
and orientation are all altered. Increasing the distance between the pyridine nitrogen and the
cationic nitrogen also appears to greatly reduce affinity across all subtypes. This is qualitatively
observed in comparing the properties of nicotine to those of Compound 8, and the properties
of Compound 1 to those of structurally related azabicylics, Compounds 5 and 11.
Comparing efficacy trends within the range of structures examined, here we noted that agonist
activity is more readily retained for both the α7 and α3β4*-nAChR subtypes than the α4β2*
and α6β2*-nAChR subtypes. This suggests that the binding pockets of the latter subtypes have
stricter structural requirements for activation than the former. For example, in the series of
Compounds 2, 1, 3 and 4, the azacyclic portion of the molecule is made progressively more
sterically demanding. Functional activity at α4β2* shifts to partial agonism and antagonism
across the series (43%, 30%, -97%, -100% efficacy compared to nicotine, Figure 4C and Table
3). Efficacy at the α6β2*-nAChR subtype appears slightly more tolerant of structural
modifications to its ligands relative to the α4β2*-nAChR. Here, the decrease in efficacy is
more gradual within the series (114%, 109%, -71%, -98%). In contrast, at α7 and α3β4*, these
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same compounds all retain agonism, with very gradually decreasing efficacy (respective
efficacy for α7, 108%, 89%, 106%, 27%; for α3β4*, 118%, 106%, 95%, 88%).
In vitro functional assays for α4β2*- and α6β2*-mediated responses identified the reference
compounds, nicotine and varenicline, as full and partial agonists, respectively. Consistent with
this identification, both of these compounds induced hypothermia in α4L9'A and locomotor
hyperactivity in α6L9'S hypersensitive mice. Likewise, Compounds 1, 2 and 10, identified as
full or partial α4β2* and α6β2* agonists in vitro, elicited hypothermia and locomotor activation
in mice expressing hypersensitive nAChRs (Table 1). Compound 8 with high efficacy at
α4β2* also induced hypothermia in α4L9'A mice. Though this compound displayed no
measurable activity at α6β2*-nAChR in WT mice in vitro, it did elicit a response in α6L9'S
mice, consistent with its agonist activity in vitro in tissue from these mutant mice (Drenan et
al, 2008). Compounds 3, 4 and 7, which were identified in vitro as α4β2* and α6β2*
antagonists, blocked the effects of nicotine in vivo, supporting the premise that they are, indeed,
bioavailable antagonists. Results with these agonists and antagonists show that they effectively
elicit the expected behavior in mice expressing the mutated receptors. However several
compounds identified as antagonists in vitro (Compounds 5, 9, and 11) did not have intrinsic
activity, nor did they block the effect of nicotine at the doses tested. In the absence of data on
bioavailability, it is not possible to determine whether the lack of effect was receptor-based or,
more likely, due to low concentration in the brain. It should be emphasized that these mice
were designed to respond to agonists at doses much lower than the doses required for wild-
type mice, so that α4* and α6*-dependent behavioral responses can be studied in the absence
of effects on other AChRs. The hypersensitive mutations are located in the M2 transmembrane
domain, some 60 Å from the agonist binding site. Thus while the present in vivo data serve
well for a qualitative assignment of agonist vs antagonist, the dose dependence in vivo is not
relevant to the wild type nAChRs. In addition, correlation between the EC50 values measured
in vitro and the effective concentrations in vivo cannot be accurately assessed since potential
differences in pharmacokinetics, metabolism and distribution leading to different exposures
have not been taken into account.
The functional characterization reported here has allowed us to achieve an important goal for
this project, namely, the identification of an agonist selective for the α6β2*-receptor. Both
Compounds 1 and 2 fulfilled the requirement for functional selectivity for α6β2* over α4β2*,
α7 and α3β4* subtypes, although greater binding selectivity might be desirable. Additionally,
both compounds exhibited in vivo activity consistent with their in vitro profiles. Major
questions remain in the design of a safe and effective smoking cessation aid. Which natural
functions of nicotinic systems must be preserved to avoid unwanted effects? What minimum
level of occupancy is effective for a smoking cessation aid? Is a short-acting agent with high
occupancy administered frequently better than one with a long half-life and low occupancy?
Is it more effective to activate receptors, to desensitize them, or to chaperone them within
intracellular compartments (Lester et al, 2009)? Will selectively targeting α6β2*nAChR prove
advantageous relative to other individual or multiple subtypes? Availability of relatively
selective, bioavailable compounds such as Compound 1 and 2 or compounds designed on the
SAR data reported here may enable research to help answer these questions.
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Figure 1. Structures of compounds assayed
For Compound 1, the methylpyrrolidine ring structure of nicotine was replaced by azabicyclo
[2.2.2]octane. The other compounds are related to Compound 1 in the following ways: the
azabicyclo structure was modified in size to [1.2.2]heptane for Compound 2, to [3.2.2]nonane
for Compound 3, and to [2.3.3.5]decane for Compound 4. An additional C was added in spacer
between ring systems to generate Compound 5. An additional C as well as a 5′ halogen group
were added to generate Compound 11. Additional bulky groups were added at the 5′ position
of the pyridine ring for Compounds 6 and 7. The methylpyrrolidine ring of nicotine was opened
up and lengthened to have 6 C between the Ns for Compound 8 and, in addition, a 5′ bulky
group added for Compound 9. For Compound 10, changes include 5′ halogen groups as well
as alternate ways of adding more space between the Ns.
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Figure 2. Inhibition of membrane binding to assess Ki values at various subtypes of nAChR
Panel A: Inhibition of binding to α4β2*-nAChR by Compound 1. High affinity [125I]-
epibatidine binding (at 200 pM) in cortical membranes, was inhibited by 11 concentrations of
Compound 1 from 0.01 nM to 1000 nM; data points are means ± sem for 6 experiments.
IC50 = 1.17 ± 0.14 nM (Ki = 0.46 ± 0.06 nM). Panel B: Inhibition of binding to α3β4*-nAChR
by Compound 1. The data were gathered with membranes prepared from IPN, a region high
in α3β4*-nAChR, using [125I]-epibatidine with A-85380 added to block binding to β2*-
nAChR. Data points are means ± sem for 3 experiments. IC50 = 12.44 ± 2.20 nM (Ki = 4.4 ±
3.6 nM). Panel C: Inhibition of binding to α7-nAChR by Compound 1. [125I]-α-bungarotoxin
binding to membranes from HP was inhibited by various concentrations of Compound 1. Data
points are means ± sem for 4 experiments. IC50 = 30.81 ± 8.39 nM (Ki = 7.6 ± 1.9 nM). Panel
D: Inhibition of binding to α6β2*-nAChR by Compound 1. [125I]-α-CtxMII binding to
membranes of combined ST, OT and SC, areas high in α6*-nAChR, was inhibited by 9
concentrations of Compound 1. Data points are means ± sem for 3 experiments. IC50 = 1.9 ±
0.6 nM (Ki = 1.14 ± 0.35 nM).
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Figure 3. Functional assays for agonist activity of Compound 1 at various subtypes of nAChR
Panel A: Function of α4β2*-nAChR measured by high sensitivity 86Rb+ efflux from thalamic
synaptosomes. EC50 values were determined by either high affinity portion of a 2-site fit of
data without DHβE (37 ± 25 nM), or by subtraction of the DHβE-resistant activity (inset) fit
to a single site (43 ± 25 nM). Panel B: Measurement of function at α4β2*-nAChR by α-CtxMII-
resistant [3H]-dopamine release and α6β2*-nAChR by α-CtxMII-sensitive [3H]-dopamine
release from striatal synaptosomes. EC50 values by curve fit, 34 ± 7 nM and 7.4 ± 1.3 nM,
respectively. Panel C: Measurement of function at α3β4*-nAChR by [3H]ACh release from
IPN synaptosomes. EC50 values by curve fit, 430 ± 190 nM. Panel D: Measurement of function
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at α7*-nAChR by relative peak current in GH4C1 cells. EC50 values by curve fit, 660 ± 370
nM. All data shown are means ± sem from 4 experiments.
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Figure 4. Comparison of parameters determined by in vitro assays
Panel A compares affinity for four subtype classes of nAChRs for a number of commonly
studied nicotinic compounds, varenicline, and the 11 compounds shown in Figure 1. Ki values
for inhibition of various selective binding assays are plotted. Dotted lines indicate 1 nM and 1
μM. Data for commonly studied nicotinic compounds are from Whiteaker et al, 2000a;Marks
et al, 1986,1993,2006;Salminen et al, 2005; unpublished data NBF, MJM. Panel B compares
potency of compounds for activation (EC50 values) or inhibition (Ki values) of four subtype
classes of nAChR. Dotted lines indicate 1 nM and 1 μM. Data for commonly studied nicotinic
compounds are from Salminen et al, 2004;Grady et al, 2001;Marks et al, 1999; unpublished
data NBF, MJM. Panel C compares efficacy for compounds as compared to nicotine for
activation or inhibition of four subtype classes of nAChR. Dotted lines indicate efficacy values
of 100% (equal to nicotine), 0 efficacy (no functional activity), and -100% (full antagonism).
Data for commonly studied nicotinic compounds are from Salminen et al, 2004;Grady et al,
2001;Marks et al, 1999; unpublished data NBF, MJM.
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Figure 5. Correlations of independent methods for assessing affinity and potency
Panel A: Comparison of potency (EC50 values) for stimulating α4β2*nAChR by measurement
of 86Rb+ efflux from thalamic synaptosomes vs. stimulating [3H]-dopamine release resistant
to α-CtxMII from striatal synaptosomes. The calculated slope is 0.98 ± 0.08, r = 0.96, and the
mean ratio of the points (0.97 ± 0.14, mean ± sem, x/y) does not differ from 1. Panel B:
Comparison of inhibition constants (Ki values, M) for nicotinic compounds measured by
inhibition of [125I]-αCtxMII binding to membranes prepared from mouse striatum, olfactory
tubercle and superior colliculus vs. constants measured by inhibition of [125I]-epibatidine
binding to membranes prepared from striata and olfactory tubercles of α4 subunit null mutant
mice. The calculated slope is 1.08 ± 0.08, r = 0.96, and the mean ratio of the points (0.88 ±
0.13, mean ± sem, x/y) does not differ from 1.
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Figure 6. Physiological assays for hypothermia in α4L9'A mice and locomotor activation in α6L9'S
mice by Compound 1
Panel A: Hypothermia measurements in α4L9'A mice to assay Compound 1 bioavailability
and in vivo activity at α4β2* nAChRs. An averaged (n = 6 mice) whole-body temperature
response in α4L9'A and WT control mice in response to an i.p. injection of Compound 1 (0.03
mg/kg) is shown. Panel B: Locomotor activation assay in α6L9'S mice to assess bioavailability
and in vivo activity at α6β2* nAChRs. Average locomotor activity (n = 8 mice) for α6L9'S and
WT control mice is shown in response to an i.p. injection of Compound 1 (0.01 mg/kg). All
data shown are means ± SEM.
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Table 1
Affinity of compounds for various binding sites as Ki values (nM)
Compound α4β2* α6β2* α7 α3β4*
Nicotine 3.50 ± 0.371 22.6 ± 9.32
44.9 ± 8.8
244 ± 73 167 ± 28
Varenicline 2.99 ± 1.01 5.5 ± 1.9
5.6 ± 1.9
42 ± 5 72.9 ± 18.9
Compound 1
TC2429/RJR2429
0.46 ± 0.06 1.14 ± 0.35
1.3 ± 0.2
7.6 ± 1.9 4.4 ± 3.6
Compound 2 7.42 ± 0.98 23.7 ± 11.6
25.2 ± 3.1
32.9 ± 1.3 88 ± 8
Compound 3
TC1698
0.98 ± 0.06 1.48 ± 0.07 2.2 ± 0.5 28 ± 8
Compound 4 16.9 ± 2.4 32.3 ± 12.0 64.5 ± 5.5 244 ± 12
Compound 5 16.1 ± 2.3 85.2 ± 23.6
83.3 ± 11.1
51.9 ± 5.0 84 ± 8
Compound 6
TC6951
1.54 ± 0.34 4.8 ± 1.67 367 ± 44 44 ± 2
Compound 7
TC2242
0.75 ± 0.31 0.56 ±0.19 23.4 ± 7.9 52 ± 4
Compound 8
RJR2403/TC2403
25.0 ± 7.2 1550 ± 210
228 ± 41
3070 ± 800 3720 ± 200
Compound 9 134 ± 26 2790 ± 660
2329 ± 443
30699 ± 4100 210000 ± 46000
Compound 10 2.31 ± 0.42 11.1 ± 0.4
2.2 ± 0.3
128 ± 36 136 ± 4
Compound 11 418 ± 53 732 ± 161 1810 ± 740 580 ± 60
Data are Ki values (nM) for inhibition of: α4β2* measured by [125I]epi binding to mouse cortical membranes; α6β2* first number measured by
[125I]-α-CtxMII binding to combined mouse ST/OT/SC membranes and, for those compounds with a second number, by [125I]epi binding to
combined mouse ST/OT/SC membranes from α4 null mutant mice; α7 measured by [125I]-α-Btx binding to mouse hippocampal membranes. (See
methods section).
1
From Whiteaker et al, 2000a.
2
From Salminen et al, 2005.
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Table 2
Potency of compounds for subtypes of nAChR as EC50 or Ki values (nM).
Compound α4β2* α6β2* α7 α3β4*
Nicotine 1610 ± 1901
1390 ± 4203
770 ± 2701 22600 ± 540 64400 ± 79002
Varenicline 50 ± 12
300 ± 100
77 ± 169 1600 ± 250 12000 ± 300
Compound 1
RJR2429/TC2429
34 ± 7
43 ± 25
7.4 ± 1.3 660 ± 150 430 ± 190
Compound 2 1040 ± 280
320 ± 100
50 ± 23 4970 ± 871 4200 ± 500
Compound 3
TC1698
14 ± 3 #
13 ± 1 #
52 ± 22 # 150 ± 57 2200 ± 300
Compound 4 78 ± 23 #
59 ± 12 #
570 ± 299 # 8500 ± 720 34000 ± 8000
Compound 5 16 ± 4 #
31 ± 4 #
370 ± 73 # 4100 ± 472 3300 ± 100
Compound 6
TC6951
230 ± 29 #
298 ± 64 #
1780 ± 1741 # 29000 ± 5400 660 ± 170 #
Compound 7
TC2242
66 ± 2 #
71 ± 20 #
48 ± 3 # 2700 ± 490 7000 ± 2000 #
Compound 8
RJR2403/TC2403
14800 ± 10100
14600 ± 4900
na 34000 ± 12900 218000 ± 81000
Compound 9 3900 ± 3400 #
6800 ±2400 #
4100 ± 83 # naa 14000 ± 300 #
Compound 10 178 ± 94
59 ± 37
117 ± 69 12270 ± 4900 7200 ± 600
Compound 11 490 ± 198 #
315 ± 108 #
910 ± 656 # 4260 ± 730 7000 ± 1000
Data are EC50 values (nM) for activation or Ki values (nM and marked with #) for inhibition of nicotine-stimulated activation and are from curve-
fits. For α4β2*, two numbers are given, the 1st is for the [3H]DA release assay, the 2nd for the 86Rb+ efflux assay.
na = no activity
naa = no agonist activity
1
From Salminen et al, 2004.
2
From Grady et al, 2001.
3
From Marks et al, 1999.
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Table 3
Efficacy of compounds for activation as % nicotine effect for activation or for % inhibition of nicotine at subtypes
of nAChR.
Compound α4β2* α6β2* α7 α3β4*
Varenicline 26 ± 2 %
29 ± 3 %
39 ± 17 % 78 ± 24 % 114 ± 12 %
Compound 1
RJR2429/TC2429
28 ± 2 %
31 ± 4 %
109 ± 7 % 89 ± 7 % 106 ± 13 %
Compound 2 64 ± 5 %
21 ±2 %
114 ± 11 % 108 ± 5 % 118 ± 5 %
Compound 3
TC1698
-94 ± 5 %
-100 ± 3 %
-71 ± 7 % 106 ± 5 % 95 ± 5 %
Compound 4 -100 ± 8 %
-100 ± 4 %
-98 ± 11 % 27 ± 4 % 88 ± 8 %
Compound 5 -98 ± 11 %
-100 ± 3 %
-96 ± 19 % 108 ± 14 % 99 ± 2 %
Compound 6
TC6951
-94 ± 2 %
-100 ± 5 %
-100 ± 19 % 18 ± 6 % -100 ± 7 %
Compound 7
TC2242
-90 ± 8 %
-100 ± 5 %
-92 ± 16 % 63 ± 11 % 103 ± 12 %
Compound 8
RJR2403/TC2403
150 ± 32 %
254 ± 21 %
0 % 17 ± 7 % 45 ± 9 %
Compound 9 -80 ± 15 %
-100 ± 5 %
-50 ± 22 % naa -100 ± 6 %
Compound 10 37 ± 4 %
63 ± 10 %
56 ± 8 % 55 ± 9 % 29 ± 1 %
Compound 11 -100 ± 9%
-100 ± 6 %
-100 ± 18 % 31 ± 12 % 8 ± 2 %
In this representation, negative numbers signify antagonists and % values are for maximum inhibitory effect on nicotine-stimulated activity. Positive
numbers are agonists and values represent maximum effect as compared to nicotine. Nicotine response at 10 μM was defined as 100% for α4β2* and
α6β2*-nAChRs, 30 μM was 100% for α3β4*, and for α7, 100% was at 200 μM nicotine and all were measured in the same experiments as the
compound. All values are as maximal release or inhibition from curve-fits of the data.
naa = no agonist activity.
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Table 4
Physiological effects in mice with hypersensitive α4β2* or α6β2*-nAChR.
Compound α4L9'Aβ2* α6L9'Sβ2*
Nicotine hypothermia (0.01)1 activation (0.1)2
Varenicline hypothermia (0.001) activation (0.1)
Compound 1
RJR2429/TC2429
hypothermia (0.03) activation (0.01)2
Compound 2 hypothermia (0.03) activation (0.1)
Compound 3
TC1698
block (0.002)
Compound 4 block (0.01)
Compound 5 no effect
Compound 6
TC6951
Compound 7
TC2242
block (0.01) block (0.1)
Compound 8
RJR2403/TC2403
hypothermia (0.2) activation (1.0)2
Compound 9 no effect
Compound 10 hypothermia (0.1) activation (0.1)
Compound 11 inconclusive
Doses are given as mg/kg.
1
From Tapper et al, 2007
2
From Drenan et al, 2008
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